The PSSD Institute is an independent nonprofit organization committed to advancing understanding of Post-SSRI Sexual Dysfunction (PSSD). Through rigorous science, collaborative partnerships, and public education, we work to address one of the most overlooked adverse effects in modern medicine.
What is Post SSRI Sexual Dysfunction?
Post-SSRI Sexual Dysfunction (PSSD) is a persistent condition where sexual and other adverse effects from antidepressant medications continue even after discontinuing the medication. While adverse effects during SSRI treatment are well-documented, PSSD represents cases where adverse symptoms persist for years or decades after stopping the medication. PSSD symptoms may first occur during treatment or at withdrawal of treatment. You can learn more about PSSD here.
Sexual Symptoms*
Reduced or absent sexual desire (libido)
Difficulty achieving arousal
Erectile dysfunction or reduced vaginal lubrication
Delayed, muted, or absent orgasm
Reduced genital sensitivity
Loss of sexual pleasure (anhedonia)
Non-Sexual Symptoms*
Emotional blunting or numbness
Loss of ability to feel pleasure (anhedonia)
Cognitive difficulties, including "brain fog"
Memory impairment
Reduced emotional range and intensity
Loss of romantic feelings or ability to "fall in love"
Loss love towards family, friends, and pets
* include but are not limited to
The Challenge
PSSD remains poorly understood in terms of its underlying mechanisms, prevalence, and treatment options. Many healthcare providers are unaware of the condition, leading to underdiagnosis and limited support for affected individuals. The lack of research funding has hindered progress in understanding this condition and developing effective treatments.
Want to get involved or have media inquiries? Please use the following links.
A 2024 cross‑sectional study found that about 13% of former antidepressant users reported persistent genital numbness (a primary and unique symptom of PSSD) compared with around 1% of people who had taken other psychiatric medications.
Some drug leafleats have been updated in Europe and North America acknowledging that sexual dysfunction symptoms may persist, but much remains unknown and more research is urgently needed.